Download MendeleyCancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric alpha D pocket.
Bancet, A., Frem, R., Jeanneret, F., Mularoni, A., Bazelle, P., Roelants, C., Delcros, J.G., Guichou, J.F., Pillet, C., Coste, I., Renno, T., Battail, C., Cochet, C., Lomberget, T., Filhol, O., Krimm, I.(2024) iScience 27: 108903-108903
- PubMed: 38318383
- DOI: https://doi.org/10.1016/j.isci.2024.108903
- Primary Citation of Related Structures:
8C5Q - PubMed Abstract:
Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and further exploring its therapeutic potential. Here, we report the discovery of AB668, an outstanding selective inhibitor that binds CK2 through a bivalent mode, interacting both at the ATP site and an allosteric αD pocket unique to CK2. Using caspase activation assay, live-cell imaging, and transcriptomic analysis, we have compared the effects of this bivalent inhibitor to representative ATP-competitive inhibitors, CX-4945, and SGC-CK2-1. Our results show that in contrast to CX-4945 or SGC-CK2-1, AB668, by targeting the CK2 αD pocket, has a distinct mechanism of action regarding its anti-cancer activity, inducing apoptotic cell death in several cancer cell lines and stimulating distinct biological pathways in renal cell carcinoma.
Organizational Affiliation:
University Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Institut Convergence Plascan, Team « Small Molecules for Biological Targets », 69373 Lyon, France.
